Meeting all primary and secondary endpoints BMS announces Phase III clinical results for mavacamten

Recently, Bristol-Myers Squibb (BMS) announced the latest phase 3 clinical trial results of a potential "first-in-class" cardiac myosin allosteric inhibitor mavacamten for the treatment of obstructive hypertrophic cardiomyopathy (oHCM)

oHCM is a chronic progressive disease that thickens the walls of the heart, making it difficult for the heart to expand properly and fill with blood, leading to a variety of debilitating symptoms and cardiac dysfunction, and is a common cause of cardiac arrest in young adults

Mavacamten is an innovative oral selective cardiac myosin allosteric modulator that targets the underlying pathophysiology of oHCM and is expected to reduce symptoms of cardiac hypercontractility in patients

The latest clinical trial results showed that after 16 weeks of treatment, 17.

Long-term extended clinical results showed that improvements in multiple measures of cardiovascular health were maintained after 48 and 84 weeks of treatment

Resting LVOT gradient was reduced by 35.

Serum NT-proBNP levels decreased by an average of 480 ng/L after 48 weeks of treatment

At 48 weeks, 67.

"The results of the extended clinical trial support the long-term use of mavacamten in symptomatic patients with oHCM

References:

[1] Bristol Myers Squibb Announces Data from EXPLORER-LTE Demonstrating Sustained Improvements in Clinically Meaningful Cardiovascular Outcomes at Weeks 48 and 84 in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy Receiving Mavacamten.

[2] Mavacamten Demonstrated Significant Reduction in Need for Septal Reduction Therapy in Symptomatic Obstructive HCM Patients in Phase 3 VALOR Trial.

Original title: Express | Expected to become blockbuster, potential "first-in-class" therapy announces latest results